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Summary
Pulmonary hypertension is a complex group of diseases characterized by a common deno-
minator: elevated pressure in the pulmonary circulation. The etiology of pulmonary hypertension 
can be very various. The first step in successful treatment of pulmonary hypertension is early de-
tection of this serious and potentially fatal disease. Very important is the suspect about the dise-
ase and send patient to additional diagnostic procedures. The most effective diagnostic method 
for screening today is echocardiogram, which can indirectly measure pressures in the pulmonary 
circulation and evaluate function of the right ventricle. The final diagnostic method proving pul-
monary hypertension is right heart catheterization. In the treatment of pulmonary hypertension 
different medications are used: calcium channel antagonists, prostaglandins, endothelin antago-
nists and inhibitors of phosphodieserase. In patients whom medical therapy is not effective lung 
transplantation remains a final step. 
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Introduction
Pulmonary hypertension is chronic disorder of pulmonary circulation which is 
characterized by elevated mean pulmonary artery pressure over 25 mmHg [1]. Dise-
ase of pulmonary vasculature leads to elevated pulmonary vascular resistance and 
elevated pulmonary artery pressure which consequently causes symptoms: exercise 
intolerance, dyspnea, weakness, presyncope and syncope and clinically meaningful 
right heart failure [2,3].
In the last decade, novel insights in pathogenesis and pathophysiology of pulmo-
nary hypertension has thought us that pulmonary hypertension is a heterogeneous 
group of disorders. Thus, according to the etiology of the disease pulmonary hyper-
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tension is divided into five groups: pulmonary arterial hypertension, pulmonary 
hypertension due to left heart disease, pulmonary hypertension due to lung disease 
and/or chronic hypoxemia, chronic thrombo-embolic pulmonary hypertension and 
pulmonary hypertension due to unclear and/or multifactorial mechanisms [4].
Symptoms and signs of pulmonary hypertension
Due to the fact that symptoms of the disease usually develop gradually, patients 
visit physicians due to the symptoms many years after pathophysiologic process 
which causes the diseases started. Typical symptoms which are reason for referring 
to physician are: exercise intolerance, shortness of breath, weakness, presyncope 
or syncope, dry cough and chest tightness. In the more advanced disease patient 
usually have peripheral edema, cynosis and finger clubbing [5,6]. Most common 
form of pulmonary hypertension, pulmonary hypertension due to left heart disea-
ses, usually is manifested in worsening of respiratory function in supine position, 
orthopnea and paroxysmal night dyspnea, whereas, such symptoms are not present 
in pulmonary arterial hypertension [6].
Detailed family medical history is essential in inherited forms of pulmonary 
arterial hypertension [7,8]. History of cocaine, amphetamine and alcohol abuse, as 
well as smoking history, can be very useful in determining the etiology of pulmo-
nary vascular disease [9,10].
Typical, but not specific signs of pulmonary hypertension can be found at de-
tailed physical examination. Neck veins distension, positive hepato - jugular reflex, 
ascites, peripheral edema and finger clubbing can be found, as well as parasternal 
drifting due to tricuspid regurgitation. Accentuated pulmonary component of se-
cond heart tone (S2), usually narrowly torn, can be heard during auscultation. In 
advanced pulmonary hypertension, holo – systolic murmur of tricuspid regurgita-
tion can be heard. 
Classification and pathogenesis of pulmonary hypertension
World Health Organization in 1973 classified pulmonary hypertension in two 
groups: primary and secondary. Development in diagnostic procedures, and better 
understanding has lead to increasing knowledge about epidemiology, pathogenesis, 
diagnostic and treatment of pulmonary hypertension has lead to Venice classificati-
on in 1998 of pulmonary hypertension into five groups. Further understanding lead 
to latest classification from Nice in 2013 which is shown in table 1. 
Regardless of the etiology of pulmonary hypertension, pulmonary hyperten-
sion is characterized by prolonged vasoconstriction, thickening and remodeling of 
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medium size pulmonary arteries and arterioles [2,3]. Prolonged vasoconstriction 
occurs due to endothelial dysfunction and misbalance between synthesis of vaso-
constrictors and vasodilators. Prolonged vasoconstriction leads to increased pulmo-
nary vascular resistance which then leads to increased right ventricular afterload 
resulting in concentric hypertrophy of right ventricle. Remodeling of pulmonary 
vasculature leads to fibrosis and obliteration of pulmonary vessels which additio-
nally increases pressure in pulmonary artery and additionally increases afterload 
of the right ventricle. Increase pulmonary vascular resistance leads to decreased 
perfusion of pulmonary vasculature and decreased oxygenation of the blood resul-
ting in hypoxemia. 
Pathogenesis of pulmonary venous hypertension due to left heart diseases is 
completely different. In this form of pulmonary hypertension there is no remode-
ling and obstruction of pulmonary vessels. Hypertension develops due to over-vo-
lume of pulmonary vessels due to systolic and/or diastolic dysfunction of the left 
ventricle or due to valvular disease of the left heart [11].
In pulmonary hypertension which develops in patients with chronic lung disea-
ses hypoxia is main pathophysiologic mechanism. Chronic hypoxia leads to prolon-
ged vasoconstriction of pulmonary vessels and then to remodeling of vessels which 
is similar to remodeling in pulmonary arterial hypertension [12].
Recurrent embolism of pulmonary vessels leads to obstruction of pulmonary 
vasculature, increase of pulmonary vascular resistance and to chronic thrombo – 
embolic pulmonary hypertension (CTEPH). CTPEH is a form of pulmonary hyper-
tension which can be successfully surgically treated with a procedure named pul-
monary thromb-enderterectomy (PEA), [13].
Separate group in classification of patients with pulmonary hypertension is 
pulmonary hypertension due to multifactorial and/or unclear mechanisms. These 
forms of pulmonary hypertension are rare and represent great challenge even in 
specialized pulmonary hypertension centers [14].
Diagnosis
Medical history and signs and symptoms are described earlier. Pulmonary arterial 
hypertension, especially idiopathic, has onset in younger age so disease usually re-
mains unrecognized for several years. Average time from first onset of symptoms 
to right diagnosis is more than two years. 
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Table 1. Classification of pulmonary hypertension




1.2.2.  ALK1, ENG, SMAD9, CAV1, KCNK3
1.2.3.  unknown
1.3 drugs and toxins induced
1.4 associated with: 
1.4.1  connective tissue diseases
1.4.2  HIV infection 
1.4.3  portal hypertension
1.4.4  congenital heart diseases
1.4.5  schistosomiasis
1’   pulmonary veno-occlusive disease (PVOD) and/or pulmonary capillary hemangiomatosis (PCH)
1’’  persistent PH of the newborn
2. Pulmonary hypertension due to left heart disease
2.1  LV systolic dysfunction
2.2  LV diastolic dysfunction
2.3  valvular disease
2.4   congenital/acquired left heart inflow/outflow tract obstruction 
and congenital cardmyopathies
3. PH due to lung diseases and/or hypoxia
3.1  COPD
3.2  interstitial lung disease
3.3  other pulmonary diseases with mixed restrictive and obstructive pattern
3.4  Sleep-disordered breathing
3.5  Alveolar hypoventilation disorders
3.6  Chronic exposure to high altitude
3.7  Developmental abnormalities
4. Chronic thromboembolic pulmonary hypertension (CTEPH) 
5. PH with unclear and/or multifactorial mechanisms 
5.1   hematological disorders: chronic hemolytic anemia, myeloproliferative disorders, 
splenectomy
5.2  systemic disorders, sarcoidosis, pulmonary histiocytosis, lymphangioleiomyomatosis
5.3  metabolic disorders: clycogen storage disease, Gaucher disease, thyroid disorders
5.4   others: tumoral obstruction, fibrosing mediastinitis, chronic renal failure  
on dialysis, segmental PH
29
Rad 522. Medical Sciences, 41(2015) : 25-33
M. Jakopović, A. Hećimović, M. Janković, M. Samaržija: Pulmonary hypertension – diagnostic and therapeutic options
Electrocardiogram can show us signs right heart axis and enlargement and 
hypertrophy of right atrium and ventricle [14,15,16]. On the chest X – ray you can see 
enlarged right heart, dilated pulmonary arteries and reduces peripheral pulmonary 
vasculature [14,15,16].
Basic screening procedure is echoradiography. With echocardiography you can 
stated that pulmonary hypertension is likely, possible and unlikely by looking at pul-
monary artery systolic pressure and tricuspid regurgitation velocity [14,17], (table 2).
Table 2. Likelihood of pulmonary hypertension on echocardiography 
PH unlikely: systolic PA ≤ 36 mmHg, TR velocity ≤ 2.8 m/sec 
PH possible: systolic PA 37 – 50 mmHg, TR velocity 2.9 – 3.4 m/sec
PH likely: systolic PA > 50 mmHg, TR velocity > 3.4 m/sec 
Patients with likely or possible pulmonary hypertension should be referred to 
expert center where further diagnostic should be performed. Right heart catheteri-
zation is fundamental diagnostic procedure for confirmation of pulmonary hyper-
tension with hemodynamic parameters and vasoreactivity testing. Vasoreactivity can 
be performed with prostanoids, adenosine and NO. Vasoreactivity testing should be 
done before starting any specific treatment of pulmonary hypertension [14,18]. 
After confirming pulmonary hypertension further test should be done to clarify 
etiology of pulmonary hypertension like: CT pulmonary angiography, ventilation 
and perfusion lung scintigraphy, pulmonary function tests, laboratory tests, genetic 
testing, liver test, HIV testing [14,18].
Treatment of pulmonary hypertension
Treatment starts with the treatment of underlying disease if known and gene-
ral measures: oxygen, oral anticoagulants, diuretics and if needed digoxin. Specific 
treatment depends on vasoreactivity testing. In group of patients with pulmonary 
arterial hypertension specific treatment is available. In patients with positive test 
(unfortunately only about 10% patients) initial treatment should be calcium channel 
blockers [19,20,21,22]. In that group of patients, normalization of pulmonary artery 
pressure is expected and these patients have good prognosis. In majority of patients 
with negative vasoreactivity testing treatment with vasodilators should be initiated. 
Vasodilators can be divided into four groups according to mechanisms of action: 
prostacyclin analogues, endothelin antagonists, phosphodiesterase 5 inhibitors and 
activators of soluble guanylate – cyclase. Vasodilators are shown in table 3. 
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Treatment usually starts with monotherapy and in patients with insufficient ef-
fects combination of two or three vasodilators of different mechanisms of action is 
recommended [14].
In patients with failure of conservative treatment surgical procedures like 
ECMO support, thromb-endarterectomy, lung and/or lung and heart transplantati-
on are indicated in selected patients [14].
Table 3. Specific vasodilators in pulmonary hypertension
Endothelin receptor antagonists bosentan, ambrisentan, macitentan
PDE – 5 inhibitors sildenafil, tadalafil
Prostacyclin analogues epoprostenol, iloprost, treprostinil, beroprost
Activators of soluble guanylate – cyclase riociguat
Follow – up
Follow up of patients is usually done with estimation of functional class, ec-
hocardiography, proNT-BNP and six-minute walking test distance. Improvement 
or deterioration in the distance walked in the test is today crucial for estimation of 
treatment efficacy [23].
Conclusion
Pulmonary hypertension is devastating, usually fatal disorder which is charac-
terized by elevated pulmonary artery pressure and pulmonary vascular resistance 
which can lead to right heart failure and consequently death. Early diagnostic is cru-
cial to improve outcome of these patients. Novel treatment options like specific pul-
monary vasodilators significantly improved outcome of patients with pulmonary 
hypertension. Surgical procedures can be life – saving options in selected patients 
in whom conservative treatment has failed. 
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Sažetak
Plućna hipertenzija – dijagnostičke i terapijske mogućnosti
Plućna hipertenzija složena je skupina bolesti koje karakterizira zajednički nazivnik: povišen 
tlak u plućnoj cirkulaciji. Etiologija plućne hipertenzije je različita. Prvi korak u uspješnom liječe-
nju plućne hipertenzije rano je otkrivanje ove teške, i potencijalno smrtonosne bolesti. Vrlo va-
žno je posumnjati na bolest te uputiti bolesnika na dodatne pretrage. Najučinkovitija dijagnosti-
čka metoda probira danas je ultrazvuk srca kojim se mogu indirektno izmjeriti tlakovi u plućnoj 
cirkulaciji te procjeniti funkcija desnog srca. Završna dijagnostička metoda kojom se dokazuje 
plućna hipertenzija je kateterizacija desnog srca. U liječenju plućne hipertenzije koriste se danas 
brojni lijekovi: antagonisti kalcijevih kanala, prostanglandini, antagonisti endotelinskih recptora 
i inhibitori fosfodiesteraze. U bolesnika u kojih medikamentozna terapija nije učinkovita ostaje 
kao zadnji korak liječenja transplantacija pluća. 
Ključne riječi: plućna hipertenzija; tlak, liječenje; idiopatska.
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